Sanofi and Regeneron Report Strong Praluent Data, Supporting Our Above-Consensus Projections
Sanofi and Regeneron announced positive outcome data for their partnered cardiovascular drug Praluent, supporting our above-consensus sales estimate for the drug and undervalued stock call for Sanofi and slightly undervalued stock call for Regeneron. We had expected the positive data, so we don’t expect any major changes to our fair value estimates for the companies. Further, the solid data reinforces both companies' moats by strengthening the value of a key drug in their portfolios.In the larg...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.